Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
₹1,158 Cr
verified against source
Revenue YoY
9.7%
reported change
EBITDA
₹152 Cr
latest reported figure
Source
screener in
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
Akums Drugs reported a strong Q4 FY26 with consolidated revenue of ₹1,158 crore (+9.7% YoY) and adjusted EBITDA of ₹152 crore (+61.6% YoY), driven by robust CDMO volume growth of over 25% in H2. The CDMO segment posted revenue of ₹952 crore (+13.4% YoY) with EBITDA margins expanding to 14.4% on operating leverage and improved product mix. Domestic branded formulations grew modestly but margins improved, while trade generics turned EBITDA positive. API business remained a drag with losses of ₹12 crore in Q4. Management guided for continued double-digit CDMO volume growth in H1 FY27, with the Zambia contract (USD 25 million annually) expected to commence by Q2 FY27 and the European CDMO contract (€35 million annual run-rate) from FY28. Capex for FY27 is planned at ₹300 crore. Key risk: sustained API price weakness or further erosion could delay the turnaround in the API segment.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects continued double-digit volume growth in CDMO for the first half of FY27, with visibility of 45-60 days.
- Commercial supplies of approximately USD 25 million from Indian facilities to Zambia expected to start by end of Q2 FY27.
- The company plans to spend around ₹300 crore on capex in FY27, primarily for oral solid capacity expansion.
- Management expects API segment losses to come down significantly in FY27, though full-year EBITDA may still be negative.
Risks flagged
- API prices remain lower than last year despite recent uptick; further decline could delay turnaround and keep losses elevated.
- Delays in regulatory approvals or tech transfer could push back revenue recognition from these large contracts.
- Management was evasive on GLP-1 strategy, citing pricing volatility; missing this opportunity could limit future growth.
- Working capital days rose from 91 to 105 due to inventory buildup; further increases could pressure cash flows.
Key quotes
- We have visibility for 45 to 60 days of our revenue book. So what we said is in Q1 Q2 as we can see we expect a double digit volume growth.
- This is an established brand already marketed with predictable volumes being sold in the European market. So once we start, we will have almost a 35 million euro on a mat basis.
- We are still evaluating when to enter at which stage to enter given the pricing still remains very volatile.
Research modules